FDA to allow Pfizer-BioNTech vaccine to be stored at higher temps: NYT (Reuters) – The U.S. Food & Drug Administration plans to approve Pfizer Inc and BioNTech SE’s request to store their COVID-19 vaccine at standard freezer temperatures instead of in ultra-cold conditions, the New York Times reported on Tuesday. The FDA is expected to […]

Johnson & Johnson is on track to roll out a single-shot coronavirus vaccine in March, and plans to have clear data on how effective it is by the end of January or early February, the U.S. healthcare company’s chief science officer said.

Scientists at the National Institutes of Health and Moderna Inc. may take about two months to determine whether doses of the company’s Covid-19 vaccine can be halved to double the supply of the shots in the U.S., according to the agency.

The United Kingdom, which was the first to grant authorization to the vaccine developed by Pfizer and Moderna, is expected to give the green light to the vaccine developed by AstraZeneca and Oxford University this week.

Ugur Sahin, founder and chief executive officer of Germany-based BioNTech, sees the potent efficacy of BNT162b2 – the vaccine developed by his company and partner Pfizer – as the possible “beginning of the end” of the coronavirus pandemic.

White House officials said they would block new vaccine guidance that would delay hurried approvals ahead of the Nov. 3 election.

AstraZeneca Plc said the company’s Covid-19 vaccine trial in the United States is still on hold.

AstraZeneca Plc paused global trials, including large late-stage studies, of the company’s experimental coronavirus vaccine because of an unexplained illness in a study participant.

The U.S. Centers for Disease Control and Prevention (CDC) asked state public health officials to prepare to distribute a potential coronavirus vaccine to high-risk groups as soon as late October, documents published by the agency showed.

Several large U.S. states are not heeding new federal health officials’ calls to reduce Covid-19 testing of some exposed to the virus, joining a broad rebuke of the Trump administration by public health leaders.